RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Curiousjfm1330 wrote: I was one of those with no hope about the label. I was sure it would reflect the phase III inclusion parameters. I am positively surpised since the label is much more permissive than I thought possible. It is actually the relatively "hidden" value in this approved drug now. I think the company will not want to say much about that publicly, but the door is completely open for ARV intolerant patients, even those not intolerant per se, but annoyed by some milder side effects could ask their doctors to be placed on Trogarzo. I don't think it will happen very quickly, but once the doctors will have experience with Trogarzo, things like that will happen. Even milder side-effects can become very annoying on the long run.
You're right, to summarize it further, clinicians should be relatively free to make the right clinical decisions for their patients, that's great for everybody.